🌍·2h agoIndustry
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
Publisher
A
Aptose Biosciences
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Aptose Biosciences
- Region
- Global
- Scope
- Industry
- Published
- June 15, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on aptose.com
Leave the platform to read the original full article on the publisher site.
Source: Aptose Biosciences
Scope: Industry
Related coverage
More related coverage
Tiziana Life Sciences·3h ago
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
Zymeworks·15h ago
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
Adial Pharmaceuticals·3d ago
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
Adial Pharmaceuticals·3d ago